All In Biotech

Drug Trial Radar · NCT02954874

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,195 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,195

Actual

Start

Jan 18, 2017

Primary completion

Aug 3, 2026

Study completion Aug 27, 2027

Sponsor

Sponsor type
NIH
First posted
Nov 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Breast Carcinoma In Situ
  • Invasive Breast Carcinoma
  • Stage I Breast Cancer AJCC v7
  • Stage II Breast Cancer AJCC v6 and v7
  • Stage III Breast Cancer AJCC v7
  • Triple-Negative Breast Carcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Patient ObservationOther

    Undergo standard monitoring

  • PembrolizumabBiological

    Given IV

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • Radiation TherapyRadiation

    Undergo radiation therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive disease-free survival (IDFS)Time frame: From date of randomization to date of first invasive recurrence, second invasive primary cancer (breast or not), or death due to any cause, assessed up to 10 years
  2. Severity of fatigueTime frame: 55 weeks after randomization
  3. Physical functionTime frame: 55 weeks after randomization

Locations

919 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Southern Cancer Center PC-Daphne

    Daphne, Alabama

  • Southern Cancer Center PC-Mobile

    Mobile, Alabama

  • Southern Cancer Center PC-Providence

    Mobile, Alabama

  • Southern Cancer Center PC-Springhill

    Mobile, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Community Cancer Institute

    Clovis, California

  • City of Hope Corona

    Corona, California

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Epic Care-Dublin

    Dublin, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Epic Care Partners in Cancer Care

    Emeryville, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Washington Health

    Fremont, California

  • Kaiser Permanente-Fresno

    Fresno, California

  • Saint Jude Medical Center

    Fullerton, California

Showing 40 of 919 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.